<?xml version="1.0" encoding="UTF-8"?>
<p id="para0006">While acknowledging all the aforementioned challenges and taking into account current recommendations and guidelines issued by the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation (EBMT) (both of which are WBMT members), here we aim to provide a consensus opinion from the WBMT, the CIBMTR's Health Services and International Studies Committee, and other HCT experts from multiple continents regarding the current worldwide threat to HCT recipients from the COVID-19 pandemic [
 <xref rid="bib0007" ref-type="bibr">7</xref>,
 <xref rid="bib0008" ref-type="bibr">8</xref>]. For Recommendations regarding the management of patients being treated with CAR T cell therapy are presented in a recent publication on this topic 
 <xref rid="bib0009" ref-type="bibr">[9]</xref>.
</p>
